Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures



Status:Recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:2 - Any
Updated:3/13/2019
Start Date:June 28, 2018
End Date:June 28, 2019
Contact:Reference Study ID: ML39791 www.roche.com/about_roche/roche_worldwide.htm
Email:global-roche-genentech-trials@gene.com
Phone:888-662-6728 (U.S. Only)

Use our guide to learn which trials are right for you!

A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures

This Phase IV, multicenter study will evaluate whether participants with Hemophilia A and
inhibitors receiving emicizumab prophylaxis can safely undergo minor surgical procedures
without additional prophylactic bypassing agents (BPA).


Inclusion Criteria:

- Age ≥ 2 years

- Ability to comply with the study protocol, in the investigator's judgment

- Diagnosis of hemophilia A and current or history of high-titer inhibitor (Bethesda
titer ≥ 5 Bethesda units)

- Plan to receive at least 4 loading doses of emicizumab and been adherent to emicizumab
prophylaxis by the time of surgery

- Undergoing minor surgery within 60 days of study enrollment. Other minor surgical
procedures could be included upon consultation and approval of Medical Monitor, but
examples include central venous catheter insertion/removal/replacement, simple dental
extractions, colonoscopy, cystoscopy, or endoscopy with biopsy, excisional skin biopsy

- Must plan to continue emicizumab prophylaxis for at least 1 month after surgery

- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive methods that result in a failure rate
of <1% per year during the study period

Exclusion Criteria:

- Diagnosis of a bleeding disorder other than hemophilia A

- Participants who have been tolerized to Factor VIII products

- Treatment with bypassing agents within 24 hours prior to surgical procedure

- Undergoing a major surgical procedure

- Previous (in the past 12 months) or current treatment for thromboembolic disease (with
the exception of previous catheter-associated thrombosis for which anti-thrombotic
treatment is not currently ongoing) or current signs of thromboembolic disease

- Other conditions (e.g., certain autoimmune diseases, including but not limited to
diseases such as systemic lupus erythematosus, inflammatory bowel disease, and
antiphospholipid syndrome) that may increase the risk of bleeding or thrombosis

- Participants who are at high risk for thrombotic microangiopathy (TMA), e.g., have a
previous medical or family history of TMA, in the investigator's judgment

- Would refuse treatment with blood or blood products, if necessary.

- Any serious medical condition or abnormality in clinical laboratory tests that, in the
investigator's judgment, precludes the participant's safe participation in and
completion of the study

- Pregnant or lactating, or intending to become pregnant during the study

- Women of childbearing potential must have a negative serum pregnancy test result
within 7 days before Study Day 1

- Treatment with any of the following: An investigational drug to treat or reduce the
risk of hemophilic bleeds within 5 half-lives of last drug administration before Study
Day 1; A non-hemophilia-related investigational drug within the last 30 days or 5
half-lives before Study Day 1 (whichever is longer); An investigational drug
concurrently

- History of clinically significant hypersensitivity associated with monoclonal antibody
therapies or components of the emicizumab injection

- Known human immunodeficiency virus (HIV) infection with CD4 count < 200
cells/microlitre within 24 weeks prior to screening
We found this trial at
17
sites
?
mi
from
Aurora, CO
Click here to add this to my saved trials
5050 Anthony Wayne Dr
Detroit, Michigan 48201
(313) 577-2424
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
(682) 885-4000
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46260
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Kansas City, Missouri 64108
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Los Angeles, California 90027
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
201 Lyons Ave
Newark, New Jersey 07112
(973) 926-7000
Newark Beth Israel Medical Center Newark Beth Israel Medical Center, a regional care, teaching hospital...
?
mi
from
Newark, NJ
Click here to add this to my saved trials
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Saint Petersburg, Florida 33701
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials